Antihypertensive drug treatment changes in the general population: the colaus study by Vanessa Christe et al.
Christe et al. BMC Pharmacology and Toxicology 2014, 15:20
http://www.biomedcentral.com/2050-6511/15/20RESEARCH ARTICLE Open AccessAntihypertensive drug treatment changes in the
general population: the colaus study
Vanessa Christe1, Gérard Waeber2, Peter Vollenweider2 and Pedro Marques-vidal1*Abstract
Background: Changes in antihypertensive drug treatment are paramount in the adequate management of patients
with hypertension, still, there is little information regarding changes in antihypertensive drug treatment in
Switzerland. Our aim was to assess those changes and associated factors in a population-based, prospective study.
Methods: Data from the population-based, CoLaus study, conducted among subjects initially aged 35–75 years and
living in Lausanne, Switzerland. 772 hypertensive subjects (371 women) were followed for a median of 5.4 years.
Data Subjects were defined as continuers (no change), switchers (one antihypertensive class replaced by another),
combiners (one antihypertensive class added) and discontinuers (stopped treatment). The distribution and the
factors associated with changes in antihypertensive drug treatment were assessed.
Results: During the study period, the prescription of diuretics decreased and of ARBs increased: at baseline,
diuretics were taken by 46.9% of patients; angiotensin receptor blockers (ARB) by 44.7%, angiotensin converting
enzyme inhibitors (ACEI) by 28.8%, beta-blockers (BB) by 28.0%, calcium channel blockers (CCB) by 18.9% and other
antihypertensive drugs by 0.3%. At follow-up (approximately 5 years later), their corresponding percentages were
42.8%, 51.7%, 25.5%, 33.0% 20.7% and 1.0%. Among all participants, 54.4% (95% confidence interval: 50.8-58.0) were
continuers, 26.9% (23.8-30.2) combiners, 12.7% (10.4-15.3) switchers and 6.0% (4.4-7.9) discontinuers. Combiners had
higher systolic blood pressure values at baseline than the other groups (p < 0.05). Almost one third (30.6%) of
switchers and 29.3% of combiners improved their blood pressure status at follow-up, versus 18.8% of continuers
and 8.7% of discontinuers (p < 0.001). Conversely, almost one third (28.3%) of discontinuers became hypertensive
(systolic ≥140 mm Hg or diastolic ≥90 mm Hg), vs. 22.1% of continuers, 16.3% of switchers and 11.5% of combiners
(p < 0.001). Multivariate analysis showed baseline uncontrolled hypertension, ARBs, drug regimen (monotherapy/
polytherapy) and overweight/obesity to be associated with changes in antihypertensive therapy.
Conclusion: In Switzerland, ARBs have replaced diuretics as the most commonly prescribed antihypertensive drug.
Uncontrolled hypertension, ARBs, drug regimen (monotherapy or polytherapy) and overweight/obesity are
associated with changes in antihypertensive treatment.
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Hypertension is an important manageable risk factor of
Cardiovascular Diseases (CVD), a major cause of morbid-
ity and mortality worldwide [1], and its prevalence has
been estimated at 36% in Switzerland [2]. Hypertension
has considerable humanistic and economic consequence
[3] and an effective and appropriate treatment must be
provided to achieve blood pressure (BP) levels < 140/
90 mmHg [4].
In many cases, a lifetime antihypertensive drug treat-
ment is recommended [3] and combination therapy is
often necessary to achieve BP control [5]. However, poor
adherence to antihypertensive drug treatment has re-
peatedly been showed: in a Canadian study, 55% of par-
ticipants on diuretics discontinued treatment after
1 year [6], and a similar discontinuation rate (53%) was
found in Italy [7]. The absence of clinical symptoms of
hypertension identifiable by the patient along with a
low tolerability of certain antihypertensive drugs are
the most common explanations why patients stop their
treatment or take their medication at inappropriate in-
tervals or wrong doses [3].
In a previous study [2], we assessed the prevalence and
management of hypertension in Switzerland. Still, there
is little if no information regarding changes in or dis-
continuation of antihypertensive drug treatment in this
country. The aim of this study was thus to assess the
therapeutic changes in hypertensive participants treated
over a period of approximately five years using data from
a population-based, prospective study and to identify the
factors associated with those changes.
Methods
The CoLaus study
The sampling procedure of the Cohorte Lausannoise
(CoLaus) study has been described previously [8]. The
CoLaus study has been accepted by the Ethics Committee
of the Canton Vaud and aims at assessing the genetic
determinants of cardiovascular disease in the Caucasian
population of Lausanne. The non-genetic part of the
CoLaus study included all participants, irrespective of
their ethnicity. Hence, only Caucasians were included in
the main study to avoid population stratification and to
increase genetic homogeneity for association studies.
Still, non Caucasian subjects were also examined (but
not included in the main study). The following inclusion
criteria were applied: (i) written informed consent; (ii) age
35–75 years; (iii) willingness to take part in the examin-
ation and to have a blood sample drawn. Recruitment
began in June 2003 and ended in May 2006. Quickly, the
complete list of the Lausanne inhabitants aged 35–75 years
(n = 56,694) was provided by the population registry of the
city and a simple, nonstratified random sample of 35%
was drawn. An invitation letter with a quick description ofthe study was sent to all randomized participants. Inter-
ested individuals were contacted telephonically within
14 days by one of the staff members who provided more
information about the study and arranged for an appoint-
ment. Participation rate was 41% and 6,733 participants
(3,544 women and 3,189 men) were recruited. In this
study, all participants, irrespective of their ethnicity, were
included.Baseline risk factor assessment
All participants attended the outpatient clinic of the
University Hospital of Lausanne in the morning after an
overnight fast (minimum fasting time 8 hours). Data
were collected by trained field interviewers in a single
visit lasting about 60 min.
Participants received a questionnaire to record infor-
mation about their status and lifestyle factors. Educational
level was stratified into basic, apprenticeship, secondary
school and university. Smoking status was classified as
never, current or former smoker. Physical activity was
defined as the practice of leisure time physical activity
at least twice per week. During a face-to-face meeting,
family history (mother and father) of myocardial infarc-
tion, stroke, hypertension, dyslipidemia or diabetes was
collected. No data was available for other first degree
relatives such as parents and siblings . Participants were
also asked if they had previously experienced myocardial
infarction, stroke or any other type of cardiovascular dis-
ease such as angina or peripheral artery disease. Personal
history of and current treatment for hypercholesterolemia
or diabetes were also determined. Information on the use
of prescription and over the counter drugs was collected,
together with their main indications. Collection was done
by asking the participant to bring the drugs to the visit
and the number of non-antihypertensive drugs prescribed
was assessed.
Body weight and height were measured in light indoor
clothes with shoes off. Body weight was measured in kilo-
grams to the nearest 100 g using a Seca® scale, which was
calibrated regularly. Height was measured to the nearest
5 mm using a Seca® height gauge. Body Mass Index (BMI)
was calculated as weight (kg) divided by the square of the
height (m). Overweight was defined by a BMI ≥25 kg/m2
and <30 kg/m2, and obesity by a BMI ≥30 kg/m2. A similar
procedure was performed at follow-up. Waist was mea-
sured with a non-stretchable tape over the unclothed
abdomen at the narrowest point between the lowest rib
and the iliac crest. Two measures were made and the
mean (expressed in centimeters) used for analyses. Ab-
dominal obesity was considered for a waist ≥ 102 cm for
men and ≥ 88 cm for women [9].
After a median follow-up time of 5.4 years (interquartile
range: 5.3–5.6 years), participants were invited to attend a
Table 1 Antihypertensive drug treatment at baseline and
follow-up, CoLaus study
Baseline Follow-up
Diuretics (%) 392 (46.9) 330 (42.8)
As main treatment (%) 93 (12.1) 108 (14.0)
Associated with other drugs (%) 293 (38.0) 240 (31.1)
Angiotensin receptor blockers (%) 345 (44.7) 399 (51.7)
Angiotensin converting enzyme inhibitors (%) 222 (28.8) 197 (25.5)
Beta-blockers (%) 216 (28.0) 255 (33.0)
Calcium channel blockers (%) 146 (18.9) 160 (20.7)
Other (%) 2 (0.3) 8 (1.0)
Number of antihypertensive classes (%)
0 - 46 (6.0)
1 368 (47.7) 293 (38.0)
2 296 (38.3) 270 (35.0)
3+ 108 (14.0) 163 (21.0)
Results are expressed as number of participants and (percentage). The total
number of participants (772) was used as denominator to calculate
percentages.
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as for baseline.
Antihypertensive drug treatment and blood pressure
status
The names of all antihypertensive drugs were collected and
coded using the Anatomical Therapeutic Chemical (ATC)
classification system [10]. In both baseline and follow-up,
antihypertensive drugs were classified into six different
categories: 1) Diuretics (isolated or associated with other
drugs); 2) Calcium channel blockers (CCBs); 3) Beta-
blockers (BBs); 4) Angiotensin-converting enzyme inhibi-
tors (ACEIs); 5) Angiotensin receptor blockers (ARB) and
6) Other (reserpine). Combinations were split into the drug
classes they contained; for example ATC code C08GA01,
corresponding to nifedipine and diuretics, was split into “di-
uretics associated with other drugs” and “calcium channel
blockers”. As a single medicine can be a combination of
up to three antihypertensive drug classes, two further
classifications were used according to the number of an-
tihypertensive drug classes or of antihypertensive pills:
monotherapy (i.e. taking a single drug class)/combination
therapy and single medicated (i.e. taking a single pill, which
can eventually be a combination of drugs)/polymedicated.
According to the evolution of their antihypertensive
treatment, participants were assigned into 4 different
groups determined by drugs brought to visit at baseline
and approximately 5 years later as suggested in a previ-
ous study [7]: 1) Continuers: participants continuing the
initial treatment (including combinations) without changes;
2) Switchers: treatment from one class to another class of
antihypertensive therapy (for example a CCB for an ARB);
3) Combiners: participants treated with an additional
type of antihypertensive class but continuing the initial
medication (for example adding a diuretic to an ARB)
and 4) Discontinuers: participants stopping the therapy
without having another antihypertensive drug prescription
added.
On baseline and follow-up, BP was measured on the
left arm, with an appropriately sized cuff. The reading
was taken following at least 10 minute rest in the seated
position, using an Omron® HEM-907 automated oscillo-
metric sphygmomanometer. Three readings were taken
and the average of the last two was used to compute sys-
tolic (SBP) and diastolic (DBP) blood pressure. A partici-
pant was considered as adequately controlled if her/his SBP
was <140 mm Hg and her/his DBP was <90 mm Hg in the
absence of diabetes, and if her/his SBP was <130 mm Hg
and her/his DBP was <80 mm Hg in the presence of
diabetes [11].
Statistical analysis
Statistical analyses were completed using Stata v.12.0
(Stata Corp, College Station, TX, USA). Results wereexpressed as number of participants (percentage) or as
mean ± standard deviation. Between-group comparisons
were performed using Chi-square for qualitative vari-
ables or Student’s t-test or one-way analysis of variance
(ANOVA) for quantitative variables. Post-hoc analyses
after ANOVA were conducted using the Scheffe method.
Multivariate analysis was conducted using Multinomial
(polytomous) logistic regression and the results were
expressed as relative risk ratio and (95% confidence inter-
val). Statistical significance was considered for p < 0.05.
Results
Sample’s characteristics
Among the 6,733 participants initially assessed, 4,973
(73.9%) had follow-up data at the present time, of which
772 (15.5%, 371 women) were treated for hypertension
at baseline. Their clinical characteristics at baseline are
summarized in Additional file 1: Table S1.
Distribution of antihypertensive drug classes
Distribution of antihypertensive drug classes at baseline
and follow-up are summarized in Table 1. At baseline,
the main antihypertensive classes were diuretics (mainly
in association with other antihypertensive drugs) and
ARBs, followed by ACE inhibitors and BBs. At follow-up,
the percentage of participants on ARBs and BBs increased
while the percentage of participants on diuretics and ACE
inhibitors decreased. At baseline, almost half of the patients
were treated with a single antihypertensive class, and less
than one sixth with 3 or more antihypertensive classes. At
follow-up, the percentage of participants treated with a sin-
gle antihypertensive class decreased, while the percentage
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classes increased to one fifth (Table 1).
Changes in antihypertensive drug treatment
Among all (mono or combination therapy) participants,
54.4% (95% confidence interval: 50.8-58.0) were con-
tinuers, 26.9% (23.8-30.2) combiners, 12.7% (10.4-15.3)
switchers and 6.0% (4.4-7.9) discontinuers (Table 2).
Among participants on monotherapy, the results wereTable 2 Baseline individual factors associated with antihyper
Continuers Combiners
N 420 (54.4) 208 (26.9)
Women (%) 213 (50.7) 93 (44.7)
Age (years) 60.2 ± 9.0 61.2 ± 8.9
Educational status (%)
Basic 94 (22.4) 46 (22.1)
Apprenticeship 186 (44.3) 90 (43.3)
High school/college 91 (21.7) 47 (22.6)
University 49 (11.7) 25 (12.0)
Smoking status (%)
Never 169 (40.2) 75 (36.1)
Former 160 (38.1) 94 (45.2)
Current 91 (21.7) 39 (18.8)
Physically active (%) 205 (48.8) 100 (48.1)
BMI (kg/m2) 28.4 ± 4.9 29 ± 4.4
BMI categories (%)
Normal 105 (25.0) 36 (17.3)
Overweight 181 (43.1) 92 (44.2)
Obese 134 (31.9) 80 (38.5)
Waist (cm) 97 ± 14 99 ± 14
Abdominal obesity (%) 219 (52.1) 121 (58.2)
Alcohol drinker (%) 301 (71.7) 160 (76.9)
Personal history of (%)
Myocardial infarction 27 (6.4) 16 (7.7)
Stroke 11 (2.6) 8 (3.9)
CVD 52 (12.4) 35 (16.8)
Dyslipidemia 182 (43.3) 105 (50.5)
Diabetes 64 (15.2) 31 (14.9)
Family history of (%)
Myocardial infarction 110 (26.2) 44 (21.2)
Stroke 88 (21.0) 35 (16.8)
Hypertension 200 (47.6) 106 (51.0)
Dyslipidemia 72 (17.1) 41 (19.7)
Diabetes 85 (20.2) 44 (21.2)
Number of other drugs §§ 2.9 ± 2.4 3.1 ± 2.5
Results are expressed as mean ± standard deviation or as number of participants a
least twice per week; §§non-antihypertensive drugs prescribed. BMI, body mass inde
of variance: NA, not assessable.42.1% (37.0-47.3), 35.9% (31.0-41.0), 13.3% (10.0-17.2)
and 8.7% (6.0-12.1).
The distribution of continuers, combiners, switchers
and discontinuers according to the pharmacological class
of the antihypertensive drug is summarized in Figure 1 for
participants on monotherapy only. The need for an add-
itional antihypertensive class (combination) were higher in
participants treated with CCBs (46.9%), ARBs (39.6%) and
diuretics (37.5%). Participants treated with ARBs, ACEIstensive drug changes, CoLaus study
Switchers Discontinuers p-value
98 (12.7) 46 (6.0)
50 (51.0) 15 (32.6) 0.08
59.2 ± 10.1 57.7 ± 8.2 0.06
22 (22.5) 10 (21.7)
37 (37.8) 18 (39.1) 0.90
26 (26.5) 9 (19.6)
13 (13.3) 9 (19.6)
43 (43.9) 19 (41.3)
35 (35.7) 18 (39.1) 0.67
20 (20.4) 9 (19.6)
56 (57.1) 26 (56.5) 0.34
27.9 ± 4.9 27.7 ± 4.2 0.15
29 (29.6) 12 (26.1)
41 (41.8) 26 (56.5) <0.05
28 (28.6) 8 (17.4)
95 ± 13 96 ± 12 0.13
48 (49.0) 16 (34.8) <0.05
74 (75.5) 31 (67.4) 0.39
2 (2.0) 1 (2.2) NA
5 (5.1) 1 (2.2) NA
11 (11.2) 6 (13.0) 0.41
39 (39.8) 19 (41.3) 0.23
10 (10.2) 4 (8.7) 0.41
26 (26.5) 14 (30.4) 0.43
23 (23.5) 10 (21.7) 0.51
49 (50.0) 27 (58.7) 0.51
19 (19.4) 12 (26.1) 0.48
20 (20.4) 12 (26.1) 0.83
3.0 ± 2.2 2.7 ± 2.7 0.80
nd (percentage). §defined as the practice of leisure time physical activity at















Continuers Combiners Switchers Discontinuers
Figure 1 Distribution of continuers, combiners, switchers and discontinuers, according to the pharmacological category of the
antihypertensive drug, CoLaus study. ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BBs, beta-blockers;
CCBs, calcium channel blockers.
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of 54.2%, 44.9% and 33.6% respectively. Finally, treatment
switching was more common among participant using di-
uretics (25.0%), CCBs (20.4%) and BBs (16.8%).
Factors associated with changes in antihypertensive drug
treatment
The associations between changes in antihypertensive
drug treatment and several personal, family and clinicalTable 3 Baseline blood pressure factors associated with antih
Continuers Combiners
N 420 (54.4) 208 (26.9)
BP status baseline
SBP (mm Hg) 137 ± 17 146 ± 19
DBP (mm Hg) 83 ± 11 86 ± 12
Hypertension§ 220 (52.4) 138 (66.4)
Antihypertensive drug
Diuretics (%) 236 (56.2) 64 (30.8)
Beta-blockers (%) 120 (28.6) 50 (24.0)
CCB (%) 76 (18.1) 42 (20.2)
ACE inhibitors (%) 119 (28.3) 58 (27.9)
ARBs (%) 224 (53.3) 82 (39.4)
Treatment regimen (%)
One pill, single drug 155 (36.9) 132 (63.5)
One pill, combination 119 (28.3) 34 (16.4)
Several pills 146 (34.8) 42 (20.2)
Results are expressed as mean ± standard deviation or as number of participants a
blood pressure ≥90 mm Hg if absence of diabetes, or as a systolic blood pressure ≥
CCB, calcium channel blockers; ACE, angiotensin converting enzyme; ARB, angioten
one-way analysis of variance.characteristics at baseline are summarized in Tables 2
and 3. Prevalence of overweight/obesity and abdominal
obesity differed between groups, but no differences were
found regarding BMI or waist levels. Conversely, no dif-
ferences were found between groups for personal and
family history, number of other prescribed drugs and
other clinical and biological variables (Table 2). SBP and
DBP differed significantly between groups: combiners
presented higher SBP values at baseline than the otherypertensive drug changes, CoLaus study
Switchers Discontinuers p-value
98 (12.7) 46 (6.0)
138 ± 16 137 ± 15 <0.001
83 ± 11 83 ± 9 <0.05
54 (55.1) 20 (43.5) <0.001
47 (48.0) 15 (32.6) <0.001
30 (30.6) 16 (34.8) 0.38
23 (23.5) 5 (10.9) 0.30
32 (32.7) 13 (28.3) 0.84
26 (26.5) 13 (28.3) <0.001
49 (50.0) 32 (69.6)
26 (26.5) 7 (15.2) <0.001
23 (23.5) 7 (15.2)
nd (percentage). §defined as a systolic blood pressure ≥140 mm Hg or diastolic
130 mm Hg or diastolic blood pressure ≥80 mm Hg if presence of diabetes.
sin receptor blockers. Statistical analysis comparing all groups by Chi-square or
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ence between combiners and continuers was statistically
significant. Combiners and discontinuers took diuretics
less frequently, while switchers took ARBs less frequently.
Combiners and discontinuers also had the highest preva-
lence of a one pill, single drug treatment (Table 3).
The results of the multivariate analysis of the factors
associated with changes in antihypertensive drug treat-
ment relative to continuers group are summarized in
Table 4. Compared to continuers, discontinuers were
less likely to be women, to take ARBs and more likely to
be on a single pill, single drug regimen. Combiners were
more likely to present with uncontrolled blood pressure
at baseline, to be on a single pill, single drug regimen
and to be overweight or obese. Switchers were less likely
to take ARBs (Table 4). No association was found between
antihypertensive drug changes and being on a single pill,
combination regimen (Table 4). Similarly, in an extended
model, no association was found between changes in
antihypertensive drug treatment and marital status,
educational level, smoking status, being physically ac-
tive, personal history of CVD, age or number of other
non-antihypertensive drugs prescribed (not shown).Impact of changes in antihypertensive drug treatment on
blood pressure status
Compared to continuers, combiners and switchers im-
proved their blood pressure status at follow-up (p < 0.001,
Table 5). Among continuers, 18.6% improved their blood
pressure while 20.7% worsened (net result: 2.1% worsen-
ing); the corresponding values for combiners were 28.9%
and 13.0% (net result: 15.9% improvement) and for
switchers 30.6% and 14.3% (net result: 16.3% improve-
ment). Finally, 8.7% of discontinuers improved theirTable 4 Multivariate analysis of the baseline factors associate
CoLaus study
Combiners
Women vs. men 0.79 (0.55 - 1.12)
ARB (yes vs. no) 0.77 (0.53 - 1.13)
Hypertension (yes vs. no) 1.69 (1.18 - 2.42)
Treatment regimen
Several pills 1 (ref)
One pill, combination 1.06 (0.63 - 1.79)
One pill, single drug 3.21 (2.06 - 5.00)
BMI status
Normal 1 (ref)
Overweight 1.83 (1.13 - 2.95)
Obese 2.35 (1.42 - 3.88)
ARB, angiotensin receptor blocker; BMI, body mass index. Statistical analysis by mul
group. Hypertension was defined as a systolic blood pressure ≥140 mm Hg or a dia
and (95% confidence interval).blood pressure while 26.1% worsened (net result: 17.6%
worsening, Table 5).
Continuers with uncontrolled BP at follow-up were
more frequently men (54.1% vs. 44.6, p = 0.05), were more
frequently uncontrolled (55.5% vs. 37.4%, p < 0.001) and
on diuretics at baseline (15.8% vs. 8.5%, p < 0.05), while
no differences were found for the other variables (not
shown).Discussion
Distribution of antihypertensive drug classes
The most commonly prescribed antihypertensive drug
classes were ARBs and diuretics, a finding in agreement
with another Swiss study [4]. The prescription rate for
ARBs at follow-up was considerably higher than re-
ported in other countries (51.7% vs. 18-36%) [12] but in
accordance with the guidelines of the Swiss Society of
Hypertension [13] and others [12]. Indeed, the Swiss
guidelines recommend that ACEIs, ARBs, CCBs and di-
uretics be first line antihypertensives, BBs being consid-
ered second line drugs. A possible reason could be the
choice of practitioners to prescribe an antihypertensive
class with the lowest side effects but just as effective as
the others [4]; further, the fact that antihypertensive
medication is reimbursed by the Swiss health system
might also induce practitioners to choose better toler-
ated, albeit more expensive antihypertensive drugs.
Conversely, the low rate of ACE inhibitor prescriptions
was not strictly in keeping with the guideline recom-
mendations at baseline [11,12], which consider ACEIs
as first-line antihypertensive drugs. This can be explained
by the fact that the guidelines recommend not to combine
ACE inhibitors with ARBs for the treatment of hyperten-
sion [12]. As ARBs are the most commonly prescribedd with changes in antihypertensive drug treatment,
Switchers Discontinuers
0.94 (0.60 - 1.48) 0.42 (0.21 - 0.81)
0.31 (0.18 - 0.52) 0.48 (0.23 - 0.98)
1.09 (0.69 - 1.72) 0.66 (0.35 - 1.23)
1 (ref) 1 (ref)
1.78 (0.94 - 3.38) 1.48 (0.49 - 4.47)
1.55 (0.88 - 2.74) 4.06 (1.68 - 9.83)
1 (ref) 1 (ref)
0.95 (0.55 - 1.66) 1.52 (0.71 - 3.24)
0.96 (0.53 - 1.76) 0.76 (0.29 - 1.98)
tinomial (polytomous) logistic regression, using continuers as the reference
stolic blood pressure ≥90 mm Hg. Results are expressed as relative risk ratio
Table 5 Evolution of blood pressure status according to
changes in antihypertensive drug treatment, CoLaus
study
Continuers Combiners Switchers Discontinuers
N 420 208 98 46
C to HT 87 (20.7) 27 (13.0) 14 (14.3) 12 (26.1)
HT to HT 142 (33.8) 78 (37.5) 24 (24.5) 16 (34.8)
C to C 113 (26.9) 43 (20.7) 30 (30.6) 14 (30.4)
HT to C 78 (18.6) 60 (28.9) 30 (30.6) 4 (8.7)
Results are expressed as number of participants and (percentage). C,
controlled blood pressure (systolic <140 mm Hg and diastolic <90 mm Hg);
HT, hypertension (systolic ≥140 mm Hg or diastolic ≥90 mm Hg). Statistical
analysis by Chi-square comparing all BP evolutions between groups: p < 0.001.
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number of ACE inhibitor prescriptions.
The recent 2013 ESH/ESC guidelines on management
of arterial hypertension indicate that diuretics, beta-
blockers, calcium antagonists, ACEI and ARBs are all suit-
able for the initiation and maintenance of antihypertensive
treatment [13]. Still, after an approximate follow-up of five
years, our results show that diuretics were more frequently
replaced and ARBs were more frequently prescribed.
Thus, our results suggest that practitioners on everyday’s
practice tend to switch from diuretics to ARB treatment.
Changes in antihypertensive drug treatment
Almost four out of ten participants (39.6%) changed
their antihypertensive drug regimen during an approxi-
mately 5.4 year follow-up (26.9% combination and 12.7%
switching), a value higher than reported previously (18%)
[4]. Conversely, the rate of discontinuers was very low
compared to other studies (Additional file 1: Table S2).
Possible reasons include more motivated, health-
conscious participants, the prescription of better toler-
ated antihypertensive drugs, and the reimbursement of
any type of antihypertensive drug by the Swiss health
insurances. Further, it has been shown that a high pro-
portion of patients discontinuing treatment are return-
ing on therapy within 1 year [6]. Hence, it is possible
that the high discontinuation rates reported in other
studies [7,14] might be overestimated due to a short
follow-up time. Overall, our results suggest that, contrary
to other countries, antihypertensive drug treatment main-
tenance is very high in Switzerland when assessed over a
period of years.
Discontinuation of diuretics was higher than all other
antihypertensive drugs. This is likely to be associated
with the well described side effects such as hypotension
and/or sodium or potassium abnormalities and/or meta-
bolic disturbance. All side effects known to be associated
with ARBs, ACEI, CCB or BB were not specifically re-
corded for this large population-based study but the
discontinuation rate is strictly in agreement with otherstudies [15,16] (Additional file 1: Table S3; for a review,
see [3]) and in accordance with adverse effects well
established in several studies [3,7-19].
Factors associated with changes in antihypertensive drug
treatment
Presence of uncontrolled hypertension was positively asso-
ciated with antihypertensive drug combination, a finding
also reported elsewhere [7]. These findings are in agree-
ment with the guidelines of the Swiss Society of Hyperten-
sion [13] and others [20] which indicate that combination
therapy should be prescribed if monotherapy fails to con-
trol blood pressure levels.
Being treated by ARBs was negatively associated with
switching or discontinuing antihypertensive drug treat-
ment, a finding in agreement with the literature [7]. The
most likely explanation is the lower rate of adverse effects
of ARBs relative to the other antihypertensive drugs [19].
Being on a one pill, single drug regimen was positively
associated with combining or discontinuing treatment.
Indeed, the single drug regimen might favor discontinu-
ation because of fewer co-morbidities and the fact that
most patients are symptom-free and might experience
more side effects from the treatment than the disease
itself [7].
Women had a lower risk of discontinuing antihyper-
tensive drug treatment, a finding in agreement with
some studies [21,22] but not with others [23]. Contrary
to previous studies [14,24], no association was found
between antihypertensive drug changes and smoking,
physical activity, marital status, educational level, per-
sonal history of cardiovascular diseases. These findings
suggest that changes in anti-hypertensive drug treat-
ment are mainly due to factors related to blood pressure
and/or to possible side effects of antihypertensive drug
treatment rather than to the socio-economic status of
the patients.
Impact of changes in antihypertensive drug treatment on
blood pressure status
Unlike larger studies [7,14,25], our study was able to as-
sess the impact of antihypertensive drug treatment on
blood pressure control. Overall, our results confirm that
adjusting the antihypertensive drug regimen leads to favor-
able changes in blood pressure status. Conversely, discon-
tinuing treatment leads to a deleterious increase in blood
pressure levels, which could partly explain the greater inci-
dence of CVD events among discontinuers [25].
Continuers with uncontrolled blood pressure at follow-
up were more frequently men, with uncontrolled blood
pressure and on diuretics at baseline. These findings sug-
gest that diuretics might be less effective in controlling
blood pressure than the other antihypertensive drugs, or
that their side effects might lead to a lower compliance
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shown to have the lowest persistence rate of all antihyper-
tensive drugs (Additional file 1: Table S3). They also indi-
cate that practitioners should be more aggressive towards
uncontrolled hypertension, as continuing the same treat-
ment will not improve blood pressure control.
Strengths and limitations
The main strength of this study is that it is population-
based and used a representative sample of subjects with
hypertension. Hence, the conclusions are applicable to
the general population and to daily clinical practice
compared to those from randomized controlled trials.
This study also allowed the analysis of a considerable
number of factors associated with antihypertensive drug
changes. Further, several studies that assessed changes in
antihypertensive drug treatment used only two [1,26,27]
or three categories such as “continuers”, “switchers” and
“discontinuers” [14]. In this study, we opted for a four-
category classification as suggested by Mazzaglia and
colleagues [7] because it reflected more accurately the
behavior of a practitioner when managing a patient with
hypertension. Indeed, our results suggest that the factors
associated with combining antihypertensive drugs are
different from those associated with maintenance of the
antihypertensive drug regimen.
This study has also some limitations. Generalization
might be limited by the modest participation rate (41%),
but this rate is comparable to other epidemiological
studies as reported by Wolff and colleagues [28]. It is also
possible that the CoLaus participants are more health-
conscious than the general population, thus biasing the
observed prevalence of discontinuers and data on past
medical history and clinical features. Unlike other studies
[29], no record of adverse effects was available; hence, the
impact of adverse effects of antihypertensive drugs could
not be assessed. Further, it was not possible to objectively
assess adherence to treatment. Compared to other studies
[14,25], our sample size was rather small but blood pres-
sure data was available while in the other studies it was
not. Hence, the effect of antihypertensive drug changes
could be objectively assessed, while the other studies
lacked such information or relied on administrative data
only. Participants might present with outdated prescrip-
tion boxes or may forget to bring a box with them. This
may have led to misclassification of the patient’s baseline
drug therapy status. No information was available regard-
ing dosage of antihypertensive drugs at baseline; thus, no
analysis of possible dosage escalation could be performed.
Similarly, for logistic and economic reasons no yearly
follow-up of the cohort could be performed, so it is pos-
sible that therapy adjustments and interventions may have
been missed. Although incidence of CVD events was
available, it was not possible to establish whether thechanges in antihypertensive drug treatment occurred be-
fore or after the occurrence of the CVD event. The next
follow-up of the cohort will start in April 2014 and will
allow evaluating the impact of antihypertensive drug treat-
ment changes in preventing CVD events Finally, we do
not know the precise reason(s) for discontinuation,
namely if it was a patient or practitioner decision.
Conclusion
In Switzerland, ARBs have replaced diuretics as the most
commonly prescribed antihypertensive drug. The percent-
age of patients with hypertension who discontinue their
treatment is considerably lower than in other countries.
Uncontrolled hypertension, ARBs, drug regimen (mono-
therapy or polytherapy) and overweight/obesity are associ-
ated with changes in antihypertensive drug treatment.
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